Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

Temporary fixes to chronic drug shortages leave Canada vulnerable

Greg Basky
CMAJ August 04, 2020 192 (31) E898-E899; DOI: https://doi.org/10.1503/cmaj.1095886
Greg Basky
Saskatoon, Sask.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Doctors and pharmacists are working around shortages of critical care medicines but warn that stop-gap measures can only stretch supplies so far.

Of the 32 drugs on Health Canada’s list of “tier 3” shortages posing the greatest threat to the health system, 24 are used in the treatment of coronavirus disease 2019 (COVID-19) or related conditions. These include key sedatives, pain medications and paralytic agents for patients on ventilators and those undergoing surgery.

Patients with COVID-19 consume these drugs at double or triple the rate of other intensive care patients. Manufacturers struggled to keep up with this additional demand as the virus spread globally and disrupted supply chains in countries like China and India. Meanwhile, the increasing consolidation of the pharmaceutical industry in recent years has meant there are fewer alternative sources for drugs and ingredients to fall back on during crises.

Rising to the crisis

So far, Canada has drawn on lessons from previous shortages to avoid major disruptions in care, says Dr. James Downar, a critical care physician at the Ottawa Hospital and head of palliative care at the University of Ottawa.

“This isn’t our first rodeo,” Downar says, recalling shortfalls of more than 1000 drugs that followed a fire at a Quebec factory in 2012. “We developed processes around that time that we’re using now. We’ve had experience figuring out how to allocate medications better and how to switch around to different classes or use different medications in the same class,” he says.

Figure

Canada may face dire shortages of critical care medicines if a second wave of COVID-19 cases spikes earlier than anticipated.

Image courtesy of iStock.com/jamesbenet

Canada has seen a steady increase in drug shortages over the past two years, with an uptick of 369 new shortages in March and April this year, compared to 163 in January and February.

In response, Health Canada issued an interim order allowing the import and sale of international versions of drugs on the tier 3 shortage list that may not meet Canadian regulatory and labelling requirements. The federal government has also issued requests for information or letters of interest to “identify additional supply” of essential critical care drugs.

In the case of the sedative propofol, Health Canada has expedited imports from the European Union, and providers can use alternatives such as ketamine (although that drug also appears on the tier 3 shortage list).

In the meantime, provinces like Ontario are collecting information on stock levels within their jurisdictions and advising hospitals on rationing existing supplies.

According to Christina Adams, chief pharmacy officer with the Canadian Society of Hospital Pharmacists, current supplies of critical care drugs should last into the fall, so long as patient volumes remain low. All bets are off, though, should Canada see a spike in cases of COVID-19 before then.

Maintaining a relative lull in cases through the summer is allowing drug manufacturers worldwide to ramp up production in anticipation of a second wave, Adams explains. But Canada’s supply chain remains vulnerable to other disruptions, “for example, a lack of raw material or trade restrictions.”

Rethinking Canada’s response

A group of physicians, pharmacists, and pharmaceutical industry insiders blames Canada’s heavy reliance on foreign manufacturers. More than a third of all drugs are produced by just 10 companies, which have increased outsourcing of all stages of production over the past two decades.

“We have driven costs so low on many generics that a lot of manufacturing has left this country and gone to the lowest cost centres in India and China,” says Dr. Kashif Pirzada, an emergency physician in Toronto and founding member of the Critical Drugs Coalition. This becomes a problem in global crises when countries like India restrict exports to shore up local supplies.

The coalition is advocating for Canada to increase domestic production of essential medicines and transparency around shortages. Although Health Canada now requires drug companies to report shortages and discontinuations, many other links in the supply chain remain opaque, says Pirzada. This includes stock levels at pharmacies across the country. “It’s a big black box, which I think needs to be cleared up,” he says.

Pirzada recognizes that manufacturing more medicines domestically would likely come with a hefty price tag (and Canada already pays some of the highest drug prices globally). But he argues that producing a “redundancy” of 10%–15% of medicines in Canada would provide a margin of safety in future crises.

Downar agrees that reducing Canada’s reliance on any one company or country makes good sense. “A number of countries and regions will probably start to try to diversify their supply chain a bit, so that we’re not as susceptible to specific events that affect one supplier,” he says.

However, Adams notes that boosting domestic production of medicines wouldn’t address shortages of active pharmaceutical ingredients, about 80% of which come from overseas. Instead, she supports building a national reserve of essential medications. The main challenge would be identifying how much to stockpile to avoid a repeat of the 2010 Tamiflu debacle, in which millions of doses expired before they could be used.

“I would say once things start to calm down with this current pandemic, there’ll be a reevaluation of how drug shortages are handled,” Adams says.

Footnotes

  • Posted on cmajnews.com on July 16, 2020

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 192 (31)
CMAJ
Vol. 192, Issue 31
4 Aug 2020
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Temporary fixes to chronic drug shortages leave Canada vulnerable
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Temporary fixes to chronic drug shortages leave Canada vulnerable
Greg Basky
CMAJ Aug 2020, 192 (31) E898-E899; DOI: 10.1503/cmaj.1095886

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Temporary fixes to chronic drug shortages leave Canada vulnerable
Greg Basky
CMAJ Aug 2020, 192 (31) E898-E899; DOI: 10.1503/cmaj.1095886
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Rising to the crisis
    • Rethinking Canada’s response
    • Footnotes
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Longer family medicine residency: Boon or bane to doctor supply?
  • The evolving picture of long COVID
  • When are shared decisions false choices?
Show more News

Similar Articles

Collections

  • Areas of Focus
    • Health services
  • Topics
    • Emergency medicine
    • Hematology & transfusion medicine
    • Medical humanities
    • Patient's perspective

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire